The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

NCT05536102 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: PLD
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Tislelizumab

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine